Pharma BD Deal Intelligence
FDA approval was won for TrueTear (intranasal neurostimulation for dry eye), triggering a $100M milestone, but the device was too costly to make and too hard to sell through eye-care offices—AbbVie pulled it from the market in August 2020, roughly three years post-launch, with no meaningful disclosed revenue.
FDA approval was won, but the product it paid for was pulled from the market within three years of launch and never generated meaningful revenue.
Full analysis, sources & comparables →Allergan to acquire Oculeve's dry eye disease development programs; reports the $125 million upfront and milestone structure for the OD-01 neurostimulation…
Allergan acquires Oculeve, adding the dry eye disease device pipeline to its eye care franchise; factual coverage of the completed transaction.
Analyst characterization of the Oculeve integration as a model 'hands-off' acquisition; Allergan CEO Brent Saunders quoted leaving the team 'exactly where they…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Allergan acquired Oculeve for $125M upfront plus commercialization milestones for OD-01, a non-invasive intranasal neurostimulation device for dry eye disease, plus an earlier-stage dry eye device program. Closed August 10, 2015. Borderline by value threshold but strategically notable for eye care franchise.
FDA approval was won, but the product it paid for was pulled from the market within three years of launch and never generated meaningful revenue.
Assessment window: 10yr post-close.
Dry eye disease is a chronic multifactorial disorder of the tear film and ocular surface, causing irritation, blurred vision, and ocular discomfort. It is driven by reduced tear production (aqueous-deficient) and/or evaporative loss (meibomian gland dysfunction), with rising prevalence linked to aging, hormonal change, and digital screen use.
At the time of the 2015 Allergan-Oculeve deal, prescription dry eye therapy was a near-monopoly led by Allergan's own Restasis (cyclosporine 0.05%) — the deal effectively gave Allergan a complementary device platform on top of its market-leading drug franchise. Competition was emerging: Shire's Xiidra (lifitegrast) approved July 2016, Sun Pharma's Cequa (cyclosporine 0.09%) in 2018, and Novartis's Xiidra acquisition in 2019 ($3.4B from Takeda). The TrueTear device represented a non-pharmacologic, drug-free alternative — the first FDA-cleared intranasal neurostimulator for dry eye, gaining authorization April 2017. Strategically the device was a differentiator versus Shire/Xiidra's pending launch and a hedge against Restasis generic erosion (Restasis lost patent protection in 2018–2020). Commercially TrueTear underperformed; Allergan discontinued the device in mid-2020 due to weak adoption against incumbent eye drops, though analysts retrospectively credited the Oculeve integration as a model 'hands-off' acquisition. The deal closed before the broader 2010s wave of dry-eye consolidation including Bausch + Lomb's Miebo (perfluorohexyloctane, 2023) and Tarsus's Xdemvy (lotilaner, 2023).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Allergan plc / Oculeve, Inc. (this deal) | 2015 | $250M | 33 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Allergan plc / SkinMedica, Inc. | 2012 | $375M | 55 |
| Allergan plc / Inamed Corporation | 2005 | $3.2B | 50 |
| Allergan plc / Zeltiq Aesthetics, Inc. | 2017 | $2.5B | 32 |
| Allergan plc / Kythera Biopharmaceuticals, Inc. | 2015 | $2.1B | 23 |
| Allergan plc / Anterios, Inc. | 2016 | $90M | 19 |
← Browse all deals · How we score deals
More: 2015 deals · Allergan plc deals · Ophthalmology deals